Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents

Solithromycin is a novel fluoroketolide antibiotic which was under investigation for the treatment of community-acquired bacterial pneumonia (CABP). A phase 1 study was performed to characterize the pharmacokinetics (PK) and safety of solithromycin in children. ABSTRACT Solithromycin is a novel fluoroketolide antibiotic which was under investigation for the treatment of community-acquired bacterial pneumonia (CABP). A phase 1 study was performed to characterize the pharmacokinetics (PK) and safety of solithromycin in children. Eighty-four subjects (median age, 6 years [age range, 4 days to 17 years]) were administered intravenous (i.v.) or oral (capsules or suspension) solithromycin (i.v., 6 to 8 mg/kg of body weight; capsules/suspension, 14 to 16 mg/kg on days 1 and 7 to 15 mg/kg on days 2 to 5). PK samples were collected after the first and multidose administration. Data from 83 subjects (662 samples) were combined with previously collected adolescent PK data (n = 13; median age, 16 years [age range, 12 to 17 years]) following capsule administration to perform a population PK analysis. A 2-compartment PK model characterized the data well, and postmenstrual age was the only significant covariate after accounting for body size differences. Dosing simulations suggested that 8 mg/kg i.v. daily and oral dosing of 20 mg/kg on day 1 (800-mg adult maximum) followed by 10 mg/kg on days 2 to 5 (400-mg adult maximum) would achieve a pediatric solithromycin exposure consistent with the exposures observed in adults. Seventy-six treatment-emergent adverse events (TEAEs) were reported in 40 subjects. Diarrhea (6 subjects) and infusion site pain or phlebitis (3 subjects) were the most frequently reported adverse events related to treatment. Two subjects experienced TEAEs of increased hepatic enzymes that were deemed not to be related to the study treatment. (The phase 1 pediatric studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01966055 and NCT02268279.)

[1]  R. Irizarry.  ggplot2 , 2019, Introduction to Data Science.

[2]  Randle Aaron M. Villanueva,et al.  ggplot2: Elegant Graphics for Data Analysis (2nd ed.) , 2019, Measurement: Interdisciplinary Research and Perspectives.

[3]  Harmeet S Deol,et al.  Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy , 2017, Drug design, development and therapy.

[4]  M. Cohen-Wolkowiez,et al.  Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid , 2017, CPT: pharmacometrics & systems pharmacology.

[5]  T. File,et al.  SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  U. Christians,et al.  Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants , 2016, CPT: pharmacometrics & systems pharmacology.

[7]  P. Smith,et al.  Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents , 2016, Antimicrobial Agents and Chemotherapy.

[8]  D. Farrell,et al.  Antimicrobial Activity of Solithromycin against Serotyped Macrolide-Resistant Streptococcus pneumoniae Isolates Collected from U.S. Medical Centers in 2012 , 2015, Antimicrobial Agents and Chemotherapy.

[9]  K. Brouwer,et al.  Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults , 2014, CPT: pharmacometrics & systems pharmacology.

[10]  R. Melano,et al.  Antimicrobial Activity of Solithromycin against Clinical Isolates of Legionella pneumophila Serogroup 1 , 2013, Antimicrobial Agents and Chemotherapy.

[11]  Nick Holford,et al.  A pharmacokinetic standard for babies and adults. , 2013, Journal of pharmaceutical sciences.

[12]  W. S. Champney,et al.  Solithromycin Inhibition of Protein Synthesis and Ribosome Biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae , 2013, Antimicrobial Agents and Chemotherapy.

[13]  M. Ratain,et al.  Nonlinear Population Pharmacokinetics of Sirolimus in Patients With Advanced Cancer , 2012, CPT: pharmacometrics & systems pharmacology.

[14]  Shuzhong Zhang,et al.  Standardized Visual Predictive Check Versus Visual Predictive Check for Model Evaluation , 2012, Journal of clinical pharmacology.

[15]  Mirjam N Trame,et al.  Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children , 2011, Clinical Cancer Research.

[16]  M. Danhof,et al.  Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? , 2011, British journal of clinical pharmacology.

[17]  S. Khoo,et al.  Lopinavir/ritonavir population pharmacokinetics in neonates and infants. , 2011, British journal of clinical pharmacology.

[18]  M. Castanheira,et al.  Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. , 2011, International journal of antimicrobial agents.

[19]  Jos H. Beijnen,et al.  Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM , 2011, Comput. Methods Programs Biomed..

[20]  D. Klepacki,et al.  Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis , 2010, Antimicrobial Agents and Chemotherapy.

[21]  Ronald N. Jones,et al.  CEM-101 Activity against Gram-Positive Organisms , 2010, Antimicrobial Agents and Chemotherapy.

[22]  David Pereira,et al.  Comparison of CEM-101 Metabolism in Mice, Rats, Monkeys and Humans , 2010 .

[23]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[24]  Gabor Grothendieck,et al.  Lattice: Multivariate Data Visualization with R , 2008 .

[25]  B. Anderson,et al.  Age and size are the major covariates for prediction of levobupivacaine clearance in children , 2006, Paediatric anaesthesia.

[26]  Amin Rostami-Hodjegan,et al.  Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.

[27]  E. Niclas Jonsson,et al.  PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..

[28]  J. Barrett,et al.  Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia , 2005, Clinical pharmacokinetics.

[29]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  Ronald N. Hines,et al.  Developmental Expression of the Major Human Hepatic CYP3A Enzymes , 2003, Journal of Pharmacology and Experimental Therapeutics.

[31]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[32]  J. Rodman,et al.  Pharmacokinetics of Azithromycin after Single‐ and Multiple‐Doses in Children , 1997, Pharmacotherapy.

[33]  S. Bhavnani,et al.  Population Pharmacokinetics of Solithromycin (CEM-101) Using Data from the Plasma and Epithelial Lining Fluid of Healthy Subjects , 1986 .